Companies › CUTISS
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EHSG-KF (denovoSkin) Autologous dermo-epidermal skin substitute | – | Phase 3 | Burns | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06745557 | EHSG-KF (denovoSkin) | Phase 3 | Burns | Other | Jun 2027 |
| NCT03229564 | EHSG-KF (denovoSkin) | Phase 2 | Burns | Other | Jun 2028 |
No annotated target.
–
Gameto Merz Aesthetics DBV Technologies Merz North America CellTherX
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.